Pharmacokinetics, metabolism, and excretion of anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in rats and rhesus monkeys

Drug Metabolism and Disposition

Volumn 38, Issue 3, 2010, Pages 459-473

  Tan, Eugene Y ^a,b   Hartmann, Georgy ^a   Chen, Qing ^a   Pereira, Antonio ^a   Bradley, Scott ^a,c   Doss, George ^a   Zhang, Andy Shiqiang ^a   Ho, Jonathan Z ^a   Braun, Matthew P ^a   Dean, Dennis C ^a,d   Tang, Wei ^a   Kumar, Sanjeev ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c ELI LILLY AND COMPANY   (United States)

^d VERTEX PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANACETRAPIB; CHOLESTEROL ESTER TRANSFER PROTEIN; DRUG METABOLITE; GLUCURONIC ACID; GLUTATHIONE;

ANIMAL EXPERIMENT; ARTICLE; BILIARY EXCRETION; CONTROLLED STUDY; DEMETHYLATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXCRETION; DRUG METABOLISM; FECES; GLUCURONIDATION; HYDROXYLATION; MALE; MASS SPECTROMETRY; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RADIOACTIVITY; RAT; RHESUS MONKEY; URINARY EXCRETION;

ANIMALS; ANTICHOLESTEREMIC AGENTS; BILE; BIOTRANSFORMATION; BLOOD CHEMICAL ANALYSIS; CHOLESTEROL ESTER TRANSFER PROTEINS; DRUG EVALUATION, PRECLINICAL; FECES; GLUCURONIDES; HYDROXYLATION; INTESTINAL ABSORPTION; MACACA MULATTA; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MOLECULAR STRUCTURE; OXAZOLIDINONES; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY; TANDEM MASS SPECTROMETRY; URINE;

MACACA MULATTA; RATTUS;

EID: 76749125435     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.109.028696     Document Type: Article

References (23)

1. Asztalos BF, Cupples LA, Demissie S, Horvath KV, Cox CE, Batista MC, and Schaefer EJ (2004) High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol 24:2181-2187.
2. Bays H and Stein EA (2003) Pharmacotherapy for dyslipidaemia- current therapies and future agents. Expert Opin Pharmacother 4:1901-1938.
3. Bloomfield D, Carlson GL, Sapre A, Tribble D, McKenney JM, Littlejohn TW 3rd, Sisk CM, Mitchel Y, and Pasternak RC (2009) Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J 157:352-360.e2.
4. Castelli WP, Abbott RD, and McNamara PM (1983) Summary estimates of cholesterol used to predict coronary heart disease. Circulation 67:730-734.
5. Clark RW, Sutfin TA, Ruggeri RB, Willauer AT, Sugarman ED, Magnus-Aryitey G, Cosgrove PG, Sand TM, Wester RT, Williams JA, Perlman ME, and Bamberger MJ (2004) Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol 24:490-497.
6. Cobain MR, Pencina MJ, D'Agostino RB Sr, and Vasan RS (2007) Lifetime risk for developing dyslipidemia: the Framingham Offspring Study. Am J Med 120:623-630.
7. Dalvie D, Chen W, Zhang C, Vaz AD, Smolarek TA, Cox LM, Lin J, and Obach RS (2008) Pharmacokinetics, metabolism, and excretion of torcetrapib, a cholesteryl ester transfer protein inhibitor, in humans. Drug Metab Dispos 36:2185-2198.
8. de Grooth GJ, Kuivenhoven JA, Stalenhoef AF, de Graaf J, Zwinderman AH, Posma JL, van Tol A, and Kastelein JJ (2002) Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation 105:2159-2165.
9. Dullaart RP, Dallinga-Thie GM, Wolffenbuttel BH, and van Tol A (2007) CETP inhibition in cardiovascular risk management: a critical appraisal. Eur J Clin Invest 37:90-98.
10. Dullaart RP, Groener JE, Dikkeschei BD, Erkelens DW, and Doorenbos H (1991) Elevated cholesteryl ester transfer protein activity in IDDM men who smoke. Possible factor for unfavorable lipoprotein profile. Diabetes Care 14:338-341.
11. Forrest MJ, Bloomfield D, Briscoe RJ, Brown PN, Cumiskey AM, Ehrhart J, Hershey JC, Keller WJ, Ma X, et al. (2008) Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol 154:1465-1473.
12. Hesler CB, Swenson TL, and Tall AR (1987) Purification and characterization of a human plasma cholesteryl ester transfer protein. J Biol Chem 262:2275-2282.
13. Howes LG and Kostner K (2007) The withdrawal of torcetrapib from drug development: implications for the future of drugs that alter HDL metabolism. Expert Opin Investig Drugs 16:1509-1516.
14. Kannel WB, Castelli WP, and Gordon T (1979) Cholesterol in the prediction of atherosclerotic disease. New perspectives based on the Framingham study. Ann Intern Med 90:85-91.
15. Krishna R, Anderson MS, Bergman AJ, Jin B, Fallon M, Cote J, Rosko K, Chavez-Eng C, Lutz R, Bloomfield DM, et al. (2007) Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies. Lancet 370:1907-1914.
16. Krishna R, Bergman AJ, Jin B, Fallon M, Cote J, Van Hoydonck P, Laethem T, Gendrano IN 3rd, Van Dyck K, Hilliard D, et al. (2008) Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects. Clin Pharmacol Ther 84:679-683.
17. 14C]anacetrapib, a novel inhibitor of the cholesteryl ester transfer protein, in humans. Drug Metab Dispos 38:474-483.
18. Linsel-Nitschke P and Tall AR (2005) HDL as a target in the treatment of atherosclerotic cardiovascular disease. Nat Rev Drug Discov 4:193-205.
19. Prakash C, Chen W, Rossulek M, Johnson K, Zhang C, O'Connell T, Potchoiba M, and Dalvie D (2008) Metabolism, pharmacokinetics, and excretion of a cholesteryl ester transfer protein inhibitor, torcetrapib, in rats, monkeys, and mice: characterization of unusual and novel metabolites by high-resolution liquid chromatography-tandem mass spectrometry and 1H nuclear magnetic resonance. Drug Metab Dispos 36:2064-2079.
20. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, and Packard CJ (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 333: 1301-1307.
21. Stamler JS, Vaughan DE, Rudd MA, Mudge GH, Kirshenbaum J, Young P, Alexander RW, and Loscalzo J (1988) Frequency of hypercholesterolemia after cardiac transplantation. Am J Cardiol 62:1268-1272.
22. Tall AR (1993) Plasma cholesteryl ester transfer protein. J Lipid Res 34:1255-1274.
23. Tall AR (2007) CETP inhibitors to increase HDL cholesterol levels. N Engl J Med 356:1364-1366.